Endoglin (CDI05) is expressed on immature blood vessels and is a marker for survival in prostate cancer

Prostate

Volumn 51, Issue 4, 2002, Pages 268-275

  Wikström, Pernilla ^a   Lissbrant, Ingela Franck ^a   Stattin, Pär ^a   Egevad, Lars ^b   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endoglin; Immunohistochemistry; Prostate cancer; Smooth muscle actin; Von Willebrand factor

Indexed keywords

ALPHA ACTIN; ANTIBODY; ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA; VON WILLEBRAND FACTOR; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD VESSEL; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MATURATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; SURVIVAL; VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036591699     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10083     Document Type: Article

References (35)

1. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
2. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
3. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
4. Microvessel density in prostate cancer: Prognostic and therapeutic utility
5. Prognostic significance of angiogenesis in clinically localized prostatic cancer (staining for factor VIII related antigen and CD34 antigen)
6. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
7. Microvessel density as a predictor of PSA recurrence after radical prostate ectomy - Comparison of CD34 and CD31
8. Assessment of tumor vascularization: Immunohistochemical and non-invasive methods
9. CD 105 and angiogenesis
10. Defective angiogenesis in mice lacking endoglin
11. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis
12. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
13. Histologic grading of prostate cancer: A perspective
14. Longterm outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer
15. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer
16. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
17. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
18. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
19. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
20. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen
21. Expression of vascular endothelial growth factor receptors in human prostate cancer
22. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma
23. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats
24. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration
25. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting
26. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer
27. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
28. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
29. Role of transforming growth factor-β1 in prostate cancer
30. Transforming growth factor-β1 over-production in prostate cancer: Effects on growth in vivo and in vitro
31. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice
32. Transforming growth factor-β: Vasculogenesis, angiogenesis, and vessel wall integrity
33. Role of activins in the male reproductive tract
34. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis